What are the possible side effects when using capmatinib?

Capmatinib is a MET inhibitor developed by Novartis specifically for patients with non-small cell lung cancer with specific gene mutations.

What are the possible side effects when using capmatinib?

Capmatinib is a targeted therapy drug for patients with non-small cell lung cancer with specific gene mutations, and some potential adverse reactions may occur during use, which are organized as follows according to the drug label:

1. Fatigue

Patients may experience persistent fatigue, listlessness, and extreme fatigue from daily activities. Fatigue can be the result of medications affecting energy metabolism, interfering with sleep cycles, or causing increased psychological stress.

2. Decreased appetite

Patients have a reduced interest in food, a marked decrease in the amount of food they eat, and may lose their appetite completely. Decreased appetite can be caused by medications acting directly on the digestive system, affecting taste, or causing psychological changes. Long-term loss of appetite can lead to health problems such as malnutrition, weight loss, etc.

What are the special drug groups for capmatinib?

In addition to side effects, the special drug population of capmatinib also deserves the attention of patients, according to the drug instructions, the special drug use groups of the drug include but are not limited to the following:

1. Pediatric patients

The use of capmatinib in the pediatric patient population has not been adequately studied to establish safety and efficacy. In the absence of clear data to support this, capmatinib is not recommended in pediatric patients.

2. Elderly patients

In the pivotal clinical trial of GEOMETRY mono-1, the results showed no significant difference in the safety and efficacy of capmatinib between older and younger patients.

This finding provides an important reference for the use of capmatinib in elderly patients, but it is still necessary to continue to monitor and evaluate the response of individual patients in clinical practice.

3. Pregnant women

Animal studies have shown that capmatinib is harmful to the fetus. In view of the lack of relevant data in human pregnancy, it is recommended that pregnant women understand the relevant precautions before taking the drug and be alert to potential risks.

[Warm tips] Patients should strictly follow the doctor's guidance when using capmatinib, pay attention to the side effects of the drug and special drug groups, and have regular relevant examinations.